| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028623831 |
| P356 | DOI | 10.1186/GM385 |
| P932 | PMC publication ID | 3580418 |
| P698 | PubMed publication ID | 23146350 |
| P5875 | ResearchGate publication ID | 233403773 |
| P50 | author | Igor Jurišica | Q23883510 |
| Paul C. Boutros | Q39184562 | ||
| Ming-Sound Tsao | Q47492209 | ||
| Melania Pintilie | Q114414745 | ||
| Maud H W Starmans | Q114414755 | ||
| P2093 | author name string | Thomas John | |
| Frances A Shepherd | |||
| Philippe Lambin | |||
| Sandy D Der | |||
| P2860 | cites work | Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma | Q23916642 |
| Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data | Q24537656 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| Profound effect of normalization on detection of differentially expressed genes in oligonucleotide microarray data analysis | Q24802706 | ||
| Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection | Q27860727 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| Comparative analysis of microarray normalization procedures: effects on reverse engineering gene networks | Q28237437 | ||
| Gene-expression profiles predict survival of patients with lung adenocarcinoma | Q29614443 | ||
| Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 | ||
| Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses | Q29616071 | ||
| Prognostic gene signatures for non-small-cell lung cancer | Q30485836 | ||
| Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control | Q30485941 | ||
| Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer | Q30497419 | ||
| Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. | Q33594867 | ||
| Gene expression-based prognostic signatures in lung cancer: ready for clinical use? | Q33988433 | ||
| Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer | Q34596148 | ||
| Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study | Q34798314 | ||
| A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies | Q35803022 | ||
| Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting | Q36709828 | ||
| Enabling personalized cancer medicine through analysis of gene-expression patterns | Q37127240 | ||
| The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours | Q39512984 | ||
| Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group | Q41508288 | ||
| Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group | Q43463195 | ||
| Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? | Q43550582 | ||
| Sample-size formula for the proportional-hazards regression model | Q47253781 | ||
| Analysis of high density expression microarrays with signed-rank call algorithms. | Q48611725 | ||
| Robust estimators for expression analysis. | Q48611734 | ||
| Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Q53390153 | ||
| Three-Gene Prognostic Classifier for Early-Stage Non–Small-Cell Lung Cancer | Q57272624 | ||
| Microarrays: retracing steps | Q57556757 | ||
| Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma | Q60185101 | ||
| Rules of evidence for cancer molecular-marker discovery and validation | Q79852778 | ||
| Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung | Q80050816 | ||
| Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer | Q80796584 | ||
| P4510 | describes a project that uses | affy | Q113334509 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| data analysis | Q1988917 | ||
| P304 | page(s) | 84 | |
| P577 | publication date | 2012-11-12 | |
| P1433 | published in | Genome Medicine | Q15816848 |
| P1476 | title | Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies | |
| P478 | volume | 4 |
| Q30764913 | Combining techniques for screening and evaluating interaction terms on high-dimensional time-to-event data |
| Q36083333 | Dealing with prognostic signature instability: a strategy illustrated for cardiovascular events in patients with end-stage renal disease |
| Q35182439 | Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences |
| Q57157404 | Prediction of early breast cancer patient survival using ensembles of hypoxia signatures |
| Q26782733 | The path to routine use of genomic biomarkers in the cancer clinic |
| Q35053798 | Toward better benchmarking: challenge-based methods assessment in cancer genomics |
Search more.